WO2006029189A2 - Topical medicament - Google Patents
Topical medicament Download PDFInfo
- Publication number
- WO2006029189A2 WO2006029189A2 PCT/US2005/031819 US2005031819W WO2006029189A2 WO 2006029189 A2 WO2006029189 A2 WO 2006029189A2 US 2005031819 W US2005031819 W US 2005031819W WO 2006029189 A2 WO2006029189 A2 WO 2006029189A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicament
- oxygen
- weight
- source
- extract
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Definitions
- the present invention is broadly concerned with improved topical medicaments in forms of creams or lotions which are useful in the treatment of a variety of conditions that are ameliorated by increased cell metabolism, circulation, and nerve function. More particularly, the invention is concerned with such medicaments having a gel base with menthol and camphor, and supplemented with potassium and an oxygen source such as an alkali metal chlorite.
- SOMBRA topically applied creams and lotions
- This product contains 3% menthol and 3% camphor, in a gel base, and is used for the temporary relief of minor aches and pains of muscles and joints associated with simple backaches, arthritis, strains, bruises, and sprains.
- the inventive medicaments comprise menthol, camphor, potassium, and a source of oxygen.
- the menthol and camphor can be individually added to the composition, or they can be added via a base composition including menthol and camphor.
- One preferred base composition is a gel sold under the name SOMBRA.
- the menthol is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20% by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight.
- the camphor is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20% by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight.
- the potassium is preferably provided in powder form, and it can be obtained from dietary supplements, for example.
- One preferred source of potassium is Potassium Chelate (99 mg potency) sold by Nature's Way.
- Potassium Chelate is provided in the form of a capsule including powder potassium and minor amounts of ground millet. The capsule can simply be opened, and the powder from the capsule used in the present invention.
- Potassium is preferably present in the medicament at a level of at least about 0.02% by weight, more preferably from about 0.04-0.5% by weight, and even more preferably from about 0.09-0.2% by weight, based upon the total weight of the medicament taken as 100% by weight.
- Potassium Chelate or a similar product preferably from about 1-20 capsules, more preferably from about 1-15 capsules, and even more preferably from about 8-13 capsules are used.
- the source of oxygen can be any source that is capable of delivering the appropriate levels of oxygen to the medicament.
- Suitable oxygen sources include those selected from the group consisting of chlorites (and preferably alkali metal chlorites such sodium chlorite and magnesium chlorite), spirulina, and mixtures of the foregoing.
- the most preferred oxygen source is sold under the name AEROBIC 07, which contains deionized water, sodium chlorite, carbonates, and bicarbonates.
- the oxygen source is preferably present in the medicament in sufficient quantities to provide oxygen levels of at least about 0.016% by weight, more preferably from about 0.10-0.85% by weight, and even more preferably from about 0.17-0.25% by weight, based upon the total weight of the medicament taken as 100% by weight.
- AEROBIC 07 or a similar product it is preferably added at levels of from about 1-13 drops, more preferably from about 1-10 drops, and even more preferably about 4 drops.
- the medicament also includes a source of chlorine ions. If sodium chlorite is used as the source of oxygen, it will also functions as a source of chlorine ions.
- Other suitable sources of chlorine ions include any chlorite (e.g., sodium hypochlorite) such as those found in commercially available bleaching agents (e.g., CLOROX, CALIBEX).
- the source of chlorine is included in sufficient quantities to provide chlorine ion levels of from about 0.10-10% by weight, and more preferably from about 0.16-0.85% by weight, based upon the total weight of the medicament taken as 100% by weight.
- the inventive medicaments can also include a number of optional ingredients, depending upon the final use.
- suitable ingredients include those selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl plyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, carbonates, bicarbonates, and mixtures of the foregoing.
- the preferred quantities of these ingredients are set forth in Table 1. These ingredients can be added individually or in a group as part of another composition (e.g., in abase composition such as SOMBRA).
- the percentages by weight are based upon the total weight of the topical medicament taken as 100% by weight.
- inventive medicaments are formed by simply mixing the above ingredients together, preferably in some type of carrier. If SOMBRA is used, then the carrier is provided by that product.
- a precursor composition containing the camphor and menthol is provided.
- the precursor composition should comprise: from about 1-10% by weight menthol, preferably from about 1-5% menthol, and even more preferably about 3% by weight menthol; and from about 1-10% by weight camphor, preferably from about 1-5% camphor, and even more preferably about 3% by weight camphor, based upon the total weight of the medicament taken as 100% by weight.
- the precursor composition can also include some or all of the optional ingredients discussed above.
- a quantity of the precursor composition is added to a container, along with a portion of the potassium. Further respective quantities of the precursor composition and potassium are then added in alternating steps until the desired quantity as been obtained.
- the precursor composition and potassium within the container are preferably then mixed until substantially homogeneous (e.g., from about 1-3 minutes, and preferably about 2 minutes). Mixing can be carried out by hand or mechanical mixing means (e.g., mixer, shearing in industrial equipment). The source of oxygen is then added to the resulting mixture and further mixing is carried out. Any optional ingredients that were not already added can then be added to the mixture to yield the final medicament.
- the inventive topical medicament is used to treat a portion of the body (human or animal) afflicted with an ailment by simply contacting the medicament with the afflicted portion of the body.
- the medicament is then preferably rubbed into the skin until it is no longer visible.
- the medicament can be used to treat numerous conditions, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain
- the inventive medicament offers a particularly significant advantage in that it achieves high metabolic activity and maintains that activity over extended periods of time.
- Metal activity refers to energy (in mV) that is created by the potassium ions in the medicament. That energy is then transferred to the patient at the medicament location on the skin. Though not wishing to be bound by theory, it is believed that the energy excites and thus opens the sodium-potassium pumps in the cells. This stimulates the nervous system and better allows active ingredients to enter the cells.
- Metabolic activity is determined by mixing 1 g of a medicament with 0.1 g of a commercially available electrolyte material (e.g., one sold under the name ORAL REHYDRATION SALTS, available from Jianas Bros. Packaging Co.). The mixture is then placed onto an electrogel pad, which is "sandwiched" between two ECG patches connected to a voltmeter. Readings in mV are taken over regular intervals (e.g., 5-minute intervals).
- a commercially available electrolyte material e.g., one sold under the name ORAL REHYDRATION SALTS, available from Jianas Bros. Packaging Co.
- a peak i.e., highest or maximum metabolic activity of at least about 2.5 mV, preferably at least about 4 mV, and more preferably from about 4-20 mV is achieved. This peak is preferably achieved within about 30 minutes, and more preferably within about 15 minutes, of application to the afflicted area.
- inventive medicaments also possess the property of having a retained metabolic activity of at least about 20%, preferably at least about 30%, and even more preferably from about 50-100% over a 45-minute time period. Furthermore, the inventive medicaments possess the property of having a retained metabolic activity of at least about 5%, preferably at least about 20%, and even more preferably from about 25-100% over an 8-hour time period. As used herein, "retained metabolic activity" is determined as follows :
- Figure Ia is a graph depicting the metabolic activity of a prior art product over a 45-minute time period
- Fig. Ib is a graph depicting the metabolic activity of another prior art product over a 45 -minute time period
- Fib. 1 c is a graph depicting the metabolic activity of the inventive medicament over a 45-minute time period; and Fig. 1 d is a graph depicting the metabolic activity of the inventive medicament over an 8-hour time period.
- a 1 -gallon plastic jug was tared on a Sunbeam Model SP5 top balance (no shield, small pan balance). The jug was then charged with 5.7 oz of SOMBRA Natural Pain Relieving Gel (available from Sombra Inc., Albuquerque, NM).
- the jug was charged with SOMBRA to a weight of 12.1 oz., and the powder from three empty capsules was added; (2) The jug was charged with SOMBRA to a weight of 1 Ib. 6.1 oz., and the powder from three empty capsules was added;
- a cap was placed on the jug, and the jug was shaken by hand for about 2 minutes to substantially evenly distribute the powder.
- the gel did not adhere to the plastic jug after the potassium amino acid chelate was added.
- AEROBIC 07 (a dietary supplement including deionized water, sodium chlorite, carbonates, and bicarbonates; available from Aerobic Live, Phoenix, AZ) was used as a stabilized source of oxygen. Thirteen drops of the Aerobic 07 were added to the plastic jug containing the SOMBRA-potassium amino acid chelate mixture. The jug was again capped and shaken by hand for about 2 minutes to yield the final topical medicament. The final medicament was more viscous than the SOMBRA gel. When comparing a quantity of each, the compounded medicament did not separate or flow as compared to the
- the topical medicament prepared in Example 1 was used to treat a patient (hereinafter referred to as "Patient A").
- Patient A was a Caucasian female in her 60s, and she was 57" and approximately 220 Ib.
- Patient A exhibited neuropathy of the legs and feet, with the left leg being worse than the right.
- Patient A's big toe on her right foot and second toe on her left foot were amputated within the preceding 3 years due to diabetes.
- Patient A also reported using Walitin (generic for Claritin) and Nasonex as needed for allergies.
- the ambient temperature during treatment ranged from 74-78°F according to measurements from four different Stress Thermometers used "as is" (Dr. Lowenstein's Model SC911 accuracy +/- 1.8°F, 10 ft. lead with fast temperature sensor).
- Patient A was recumbent on a treatment table with a triangular pillow positioned behind both knees so that the knees were bent upward to rise above the ankles.
- a temperature probe was strapped on each upper ventral thigh and on the inside of each ankle. The probes were covered, and no medicament was applied to the probes.
- Equilibration time was approximately 10 minutes after the patient reclined in the prone position. After equilibration time was reached, the temperatures were recorded as shown in Table C.
- the inventive medicament was applied to the top and bottom of each thigh and later (as shown in Table D) to the top and bottom of each calf, ankle, and foot.
- the product was massaged into the skin until nearly invisible to the eye.
- the dosage level was 0.3 oz. on each thigh and each ankle for a total per leg dosage of 0.6 oz.
- Patient A rose from the table at 78 minutes, and the thigh probes were removed. Patient A held the readout portion of the thermometers in her hand while the probes were still attached to the ankles to allow her to walk to the restroom and take a further readout of her ankles after 5 minutes elapsed. However, at 82 minutes the left ankle probe came loose so no reading was taken. The right ankle probe gave a reading of 81.1 0 F at 82 minutes. Patient A reported that her left side (neuropathic side) felt soothed.
- Example 1 The topical medicament prepared in Example 1 was used to treat a second patient
- Patient B was a 60-year old, 57", Caucasian female. She was a non-insulin dependent diabetic and had sensory neuropathy that was worse in her right leg. She did not have any visible wounds. Her daily oral medications were Glucophage (1 in the evening), Toprol, Diovan, and Lipitor (1 in the evening). 2. Treatment with Inventive Topical Medicament
- the ambient temperature during treatment ranged from 74-75 0 F according to measurements from the four different Stress Thermometers as described in Part 2 of Example 2.
- the probes were applied as described in Part 2 of Example 2.
- the initial readings are shown in Table E.
- Fig. Ia shows the metabolic activity of one prior art product (non-modified SOMBRA) over a 45-minute time period.
- Fig. Ib shows the metabolic activity of another prior art product (non- modified BIO-FREEZE) over a 45-minute time period.
- Fig. Ic shows the inventive medicament's metabolic activity over a 45-minute time period.
- a comparison of these figures shows that metabolic activity of the prior art peaks and then drops substantially over the 45-minute time period while the inventive medicament's metabolic activity maintains very high levels even after peaking.
- Fig. Id shows the inventive medicament's metabolic activity over an 8-hour time period. This graph shows that this activity drops slowly over the 8-hour time period, thus providing prolonged treatment periods as compared to prior art products.
- Patient C Treatment of Patient with Inventive Topical Medicament
- the patient in this example (hereinafter referred to as "Patient C") was a Caucasian female in her late 50s.
- Patient C was suffering from neuropathy in her feet, with symptoms including sharp, stabbing pains and contractures due to over-stimulation of muscles.
- the condition had caused Patient C to take disability from work.
- the topical medicament prepared in Example 1 was applied to Patient Cs feet.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005282502A AU2005282502B2 (en) | 2004-09-08 | 2005-09-07 | Topical medicament |
GB0704141A GB2432314B (en) | 2004-09-08 | 2005-09-07 | Topical medicament comprising menthol, camphor, potassium and a source of oxygen |
CA2579338A CA2579338C (en) | 2004-09-08 | 2005-09-07 | A topical medicament comprising menthol,camphor,potassium, and a source of oxygen |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60813604P | 2004-09-08 | 2004-09-08 | |
US60/608,136 | 2004-09-08 | ||
US11/220,138 | 2005-09-06 | ||
US11/220,138 US7704522B2 (en) | 2004-09-08 | 2005-09-06 | Topical medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006029189A2 true WO2006029189A2 (en) | 2006-03-16 |
WO2006029189A3 WO2006029189A3 (en) | 2007-05-03 |
Family
ID=35996542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/031819 WO2006029189A2 (en) | 2004-09-08 | 2005-09-07 | Topical medicament |
Country Status (5)
Country | Link |
---|---|
US (3) | US7704522B2 (en) |
AU (1) | AU2005282502B2 (en) |
CA (1) | CA2579338C (en) |
GB (1) | GB2432314B (en) |
WO (1) | WO2006029189A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017004319A1 (en) | 2015-07-01 | 2017-01-05 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
US10154984B2 (en) * | 2015-07-01 | 2018-12-18 | Twi Biotechnology, Inc. | Diacerein or Rhein topical formulations and uses thereof |
US10512625B2 (en) * | 2015-07-01 | 2019-12-24 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
US7811554B2 (en) | 2007-01-19 | 2010-10-12 | Flavio Lozano | Horse liniment |
EP3000487B8 (en) | 2007-02-19 | 2022-06-15 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
WO2009006701A1 (en) * | 2007-07-12 | 2009-01-15 | Peter O'gorman | Topical medicament |
EP2042167A1 (en) * | 2007-09-26 | 2009-04-01 | Aisa Therapeutics | Use of a monoterpene to induce tissue repair |
US20110021958A1 (en) * | 2009-07-27 | 2011-01-27 | Lynds Bruce G | Therapeutic Devices And Methods Of Using The Same |
NZ703163A (en) | 2010-04-15 | 2016-06-24 | Marinepolymer Tech Inc | Anti-bacterial applications of poly-n-acetylglucosamine nanofibers |
ES2712098T3 (en) | 2011-04-15 | 2019-05-09 | Marine Polymer Tech Inc | Treatment of HSV infections with poly-N-acetylglucosamine nanofibers |
US20130072575A1 (en) * | 2011-09-19 | 2013-03-21 | Johnson & Johnson Consumer Companies, Inc. | Method and Composition for Treating Pain |
US9717757B1 (en) | 2011-12-28 | 2017-08-01 | Samuel N. Gasque, Jr. | Composition and method to treat and prevent muscle cramping |
WO2014193972A1 (en) * | 2013-05-29 | 2014-12-04 | Kirkpatrick Melissa | Topical examination compositions and methods |
CN106620154A (en) * | 2015-11-03 | 2017-05-10 | 聂金莲 | Impediment pain plaster |
US10265079B2 (en) * | 2016-04-28 | 2019-04-23 | Grena Usa Llc | Polymeric ligating clip |
CA3199914A1 (en) * | 2020-11-25 | 2022-06-02 | Steven M. Hernandez | Scar treatment composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855922A (en) * | 1995-12-07 | 1999-01-05 | Bio-Cide International, Inc. | Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders |
US5955067A (en) * | 1996-07-23 | 1999-09-21 | Oge; Eray | Potassium-containing composition useful in the treatment of acne, psoriasis and seborrhea |
US6328982B1 (en) * | 1998-08-04 | 2001-12-11 | Takasago International Corporation | Cool feeling composition |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2045618B (en) * | 1979-04-03 | 1983-05-11 | Hisamitsu Pharmaceutical Co | Adhesive plaster |
DE3213389A1 (en) * | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | STABILIZED ACTIVATED OXYGEN AND MEDICINAL PRODUCTS CONTAINING THIS STABILIZED ACTIVATED OXYGEN |
DE3344691A1 (en) * | 1983-12-10 | 1985-06-20 | Bayer Ag, 5090 Leverkusen | ACTIVE GAS EXHAUST SYSTEMS |
DE3347277A1 (en) * | 1983-12-28 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | ACTIVE SUBSTANCE DELIVERY SYSTEMS |
DE3347278A1 (en) * | 1983-12-28 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | ACTIVE SUBSTANCE DELIVERY SYSTEMS |
DE3409079A1 (en) * | 1984-03-13 | 1985-09-19 | Bayer Ag, 5090 Leverkusen | MEDICAL PLASTER |
US4892890A (en) * | 1984-11-01 | 1990-01-09 | G. D. Searle And Company | External analgesic compositions |
LU85643A1 (en) * | 1984-11-16 | 1986-06-04 | Oreal | THERMAL-SLIMMING COSMETIC COMPOSITION BASED ON OLEOSOLUBLE PLANT EXTRACTS |
JPS61293911A (en) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | Sustained release preparation |
US4702916A (en) * | 1985-12-03 | 1987-10-27 | Warner-Lambert Company | Analgesic stick compositions |
US4963591A (en) * | 1985-12-16 | 1990-10-16 | Carter-Wallace Inc. | Cosmetic compositions |
US5145675A (en) * | 1986-03-31 | 1992-09-08 | Advanced Polymer Systems, Inc. | Two step method for preparation of controlled release formulations |
JPS62169723A (en) * | 1986-01-22 | 1987-07-25 | Teisan Seiyaku Kk | Sustained release preparation |
DE3704907A1 (en) * | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
DE69020900T2 (en) * | 1989-07-28 | 1995-12-14 | Hisamitsu Pharmaceutical Co | FOAM AEROSOL COMPOSITION. |
US5383848A (en) * | 1990-04-12 | 1995-01-24 | Gensia, Inc. | Iontophoretic administration of drugs |
US5273754A (en) * | 1992-03-27 | 1993-12-28 | Mann Morris A | Appetite suppressant composition and method relating thereto |
US5429590A (en) * | 1992-12-01 | 1995-07-04 | Nitto Denko Corporation | Medical water-absorptive polymer and dressing for wound and medical bandage using the same |
HUT67748A (en) * | 1993-07-27 | 1995-04-28 | Biogal Gyogyszergyar | Hair tonic composition |
DE4341444C2 (en) * | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Active substance-containing plaster and process for its production |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5597849A (en) * | 1994-11-14 | 1997-01-28 | Medical Polymer Technologies, Inc. | Stick formulations for topical drug delivery of therapeutic agents and uses thereof |
US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5804203A (en) * | 1994-12-21 | 1998-09-08 | Cosmederm Technologies | Topical product formulations containing strontium for reducing skin irritation |
US6139850A (en) * | 1994-12-21 | 2000-10-31 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
IT1275955B1 (en) * | 1995-03-22 | 1997-10-24 | Dompe Spa | PHARMACEUTICAL FORMULATIONS IN THE FORM OF THISSOTROPIC GEL |
US5866143A (en) * | 1995-03-24 | 1999-02-02 | El Khoury And Stein, Ltd. | Topical application of opioid drugs such as morphine for relief of itching and skin disease |
HU213450B (en) * | 1995-04-26 | 1997-06-30 | Ladanyi Jozsef | Gel contains gelatin and process for producing it |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
WO1996040192A1 (en) * | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
EP0750905B1 (en) * | 1995-06-27 | 2003-01-02 | Kao Corporation | Patch comprising water soluble adhesive sheet |
US5626856A (en) * | 1995-06-30 | 1997-05-06 | Safe & Dry Company, Inc. | Cosmetic delivery vehicles and related compositions |
US5882663A (en) * | 1995-10-20 | 1999-03-16 | Koeniger; Erich A. | Topical pain-relieving preparation containing C12 To C18 isoparaffins |
US6239180B1 (en) * | 1995-11-08 | 2001-05-29 | The Regents Of The University Of California | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
TW452494B (en) * | 1996-03-12 | 2001-09-01 | Jang De Shan | Herbal composition for stimulating blood circulation |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US5830447A (en) * | 1996-09-04 | 1998-11-03 | The Procter & Gamble Company | Personal care compositions |
US5863527A (en) * | 1996-09-04 | 1999-01-26 | The Proctor & Gamble Company | Personal care compositions |
US5804173A (en) * | 1996-09-04 | 1998-09-08 | The Procter & Gamble Company | Personal care compositions |
US5916548A (en) * | 1996-09-04 | 1999-06-29 | The Procter & Gamble Company | Personal care compositions |
US6440987B1 (en) * | 1996-11-25 | 2002-08-27 | Toray Industries, Inc. | Antipruritic |
ATE291429T1 (en) * | 1996-11-25 | 2005-04-15 | Toray Industries | REMEDIES FOR ITCHING |
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
CA2291335A1 (en) * | 1997-05-27 | 1998-12-03 | Algos Pharmaceutical Corporation | Analgesic drug composition containing a capsaicinoid and potentiator therefor |
JP4677063B2 (en) * | 1997-07-18 | 2011-04-27 | 帝國製薬株式会社 | Dutch mustard extract combination external preparation |
DE19749467C2 (en) * | 1997-11-08 | 1999-09-23 | Beiersdorf Ag | Active substance-containing patches |
US5980925A (en) * | 1997-12-30 | 1999-11-09 | Ethicon, Inc. | High glycerin containing anti-microbial cleansers |
US6103266A (en) * | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
US6252003B1 (en) * | 1998-06-04 | 2001-06-26 | Kao Corporation | Polymer emulsion and process for producing the same |
US6284234B1 (en) * | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
US6258857B1 (en) * | 1999-02-04 | 2001-07-10 | Kyowa Industrial Co., Ltd. | Internal liquid composition contained as internal liquid in a releasing container and releasing container product |
US6277401B1 (en) * | 1999-05-07 | 2001-08-21 | U.S. Dermatologics, Inc. | Drug delivery device |
US6495498B2 (en) * | 1999-05-27 | 2002-12-17 | Johnson & Johnson Consumer Companies, Inc. | Detergent compositions with enhanced depositing, conditioning and softness capabilities |
US6524594B1 (en) * | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
US6335023B1 (en) * | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
JP3724988B2 (en) * | 1999-07-30 | 2005-12-07 | 信越化学工業株式会社 | Novel silicone compound and cosmetic comprising the same |
US6270783B1 (en) * | 1999-08-13 | 2001-08-07 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic strips with liquid crystal temperature dependent color change |
US6306412B1 (en) * | 1999-08-13 | 2001-10-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic strip with an agent for inducing a temperature change |
US6653352B2 (en) * | 1999-09-29 | 2003-11-25 | Medical Merchandising, Inc. | Pain reliever and method of use |
US6348218B1 (en) * | 1999-10-04 | 2002-02-19 | Invent Resources, Inc. | Self dosing skin preparation |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6645520B2 (en) * | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
DE10001546A1 (en) * | 2000-01-14 | 2001-07-19 | Beiersdorf Ag | Process for the continuous production and coating of self-adhesive compositions based on polyisobutylene with at least one active pharmaceutical ingredient |
US6635702B1 (en) * | 2000-04-11 | 2003-10-21 | Noveon Ip Holdings Corp. | Stable aqueous surfactant compositions |
US6623756B1 (en) * | 2000-04-27 | 2003-09-23 | Noveon Ip Holdings Corp. | Directly compressed solid dosage articles |
US6409997B1 (en) * | 2000-07-31 | 2002-06-25 | Neutrogena Corporation | Wax cosmetic stick |
US6433061B1 (en) * | 2000-10-24 | 2002-08-13 | Noveon Ip Holdings Corp. | Rheology modifying copolymer composition |
WO2002057215A2 (en) * | 2001-01-16 | 2002-07-25 | Theravance, Inc. | Sodium channel modulators |
EA200300622A1 (en) * | 2001-01-31 | 2003-12-25 | Пфайзер Продактс Инк. | DERIVATIVES OF AMIDES TIAZOLYL-, OXAZOLYL, PYRROLYL-AND IMIDAZOZYL ACID, USEFUL AS AN INHIBITORS OF PDE4 ISOFERMENT |
MXPA03006887A (en) * | 2001-01-31 | 2003-11-13 | Pfizer Prod Inc | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes. |
US6589568B2 (en) | 2001-02-16 | 2003-07-08 | Nurad, Inc. | Therapeutic body lotion containing alkali metal hypohalite |
US6592896B2 (en) * | 2001-08-06 | 2003-07-15 | The Quigley Corporation | Medicinal composition and method of using it |
US6596313B2 (en) * | 2001-08-06 | 2003-07-22 | The Quigley Corporation | Nutritional supplement and methods of using it |
US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US7704522B2 (en) | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
-
2005
- 2005-09-06 US US11/220,138 patent/US7704522B2/en not_active Expired - Fee Related
- 2005-09-07 AU AU2005282502A patent/AU2005282502B2/en not_active Ceased
- 2005-09-07 WO PCT/US2005/031819 patent/WO2006029189A2/en active Application Filing
- 2005-09-07 CA CA2579338A patent/CA2579338C/en not_active Expired - Fee Related
- 2005-09-07 GB GB0704141A patent/GB2432314B/en not_active Expired - Fee Related
-
2007
- 2007-10-03 US US11/866,573 patent/US8541034B2/en not_active Expired - Fee Related
-
2008
- 2008-09-18 US US12/233,444 patent/US8048447B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855922A (en) * | 1995-12-07 | 1999-01-05 | Bio-Cide International, Inc. | Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders |
US5955067A (en) * | 1996-07-23 | 1999-09-21 | Oge; Eray | Potassium-containing composition useful in the treatment of acne, psoriasis and seborrhea |
US6328982B1 (en) * | 1998-08-04 | 2001-12-11 | Takasago International Corporation | Cool feeling composition |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017004319A1 (en) | 2015-07-01 | 2017-01-05 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
JP2018522875A (en) * | 2015-07-01 | 2018-08-16 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドTWI Biotechnology, Inc. | Diacerein or Rain topical formulation and use thereof |
US10154984B2 (en) * | 2015-07-01 | 2018-12-18 | Twi Biotechnology, Inc. | Diacerein or Rhein topical formulations and uses thereof |
US10512625B2 (en) * | 2015-07-01 | 2019-12-24 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
AU2016287636B2 (en) * | 2015-07-01 | 2021-09-16 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2006029189A3 (en) | 2007-05-03 |
US20060051432A1 (en) | 2006-03-09 |
US20090017138A1 (en) | 2009-01-15 |
GB2432314B (en) | 2009-10-28 |
CA2579338C (en) | 2014-07-08 |
CA2579338A1 (en) | 2006-03-16 |
AU2005282502A1 (en) | 2006-03-16 |
US8048447B2 (en) | 2011-11-01 |
US7704522B2 (en) | 2010-04-27 |
GB2432314A (en) | 2007-05-23 |
US20080069903A1 (en) | 2008-03-20 |
US8541034B2 (en) | 2013-09-24 |
GB0704141D0 (en) | 2007-04-11 |
AU2005282502B2 (en) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005282502B2 (en) | Topical medicament | |
TWI345470B (en) | Homeopathic formulations useful for treating pain and/or inflammation | |
TWI345451B (en) | Use of means to supply carbon dioxide for increasing muscle force and a method to increase meat production of livestock thereby | |
JP5622775B2 (en) | Composition for treating dermatosis, formulation using the same, and preparation method thereof | |
CN101773577A (en) | Kanto tea bath package for curing rheumatism, arthritis and senile degenerative joint diseases | |
EP3369428B1 (en) | External traditional chinese medicine preparation for diminishing inflammation, relieving pain and promoting fast healing, and preparation method therefor | |
AU2005291420B2 (en) | Use of lavender oil for the prophylaxis and treatment of neuro asthenia, somatization disorders and other diseases associated with stress | |
CA2730009C (en) | Topical medicament | |
EP0841895B1 (en) | Slimming cream based on plants | |
KR100998990B1 (en) | Composition for slimming | |
US20180169071A1 (en) | Nutritional supplement composition | |
CN115531446A (en) | Application of composition in preparing medicine for diminishing inflammation, relieving pain and healing wound | |
WO2003061676A1 (en) | Compositions for and method of treatment for skin ailments | |
JP6735489B2 (en) | Therapy Oil with Natural Ore Powder | |
CN101904958A (en) | Oral medicinal composition for treating fracture | |
RU2517217C1 (en) | Agent for preventing chronic fatigue syndrome in males | |
US20160101141A1 (en) | Topical Treatment of Sports Related Injuries | |
CN107875224A (en) | A kind of spontaneous heating external application Traditional Chinese medicine used as analgesic composition and preparation method thereof | |
KR102607583B1 (en) | Skin external appliction composition for muscle fatigue recovery and muscle pain alleviating and Manufacturing method thereof | |
AU2008274908B2 (en) | Topical medicament | |
US20240091290A1 (en) | Pharmaceutical composition for relieving pain from joint and muscle strain | |
CN102357222B (en) | Muscle-relaxing blood-invigorating pain-relieving paste and preparation method thereof | |
CN101926922B (en) | Chinese patent medicament for treating cerebrovascular diseases and preparation method thereof | |
KR20200131787A (en) | Lymphatic circulation promotive food composition | |
CN111420020A (en) | A pure natural composition for treating pain and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2579338 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 0704141 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20050907 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0704141.1 Country of ref document: GB |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2007/002724 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005282502 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005282502 Country of ref document: AU Date of ref document: 20050907 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005282502 Country of ref document: AU |
|
122 | Ep: pct application non-entry in european phase |